These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 29515122

  • 1. Pan-class I  PI3-kinase inhibitor BKM120 induces MEK1/2-dependent mitotic catastrophe in non-Hodgkin lymphoma leading to apoptosis or polyploidy determined by Bax/Bak and p53.
    Müller A, Gillissen B, Richter A, Richter A, Chumduri C, Daniel PT, Scholz CW.
    Cell Death Dis; 2018 Mar 07; 9(3):384. PubMed ID: 29515122
    [Abstract] [Full Text] [Related]

  • 2. Antitumor activity of NVP-BKM120--a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells.
    Koul D, Fu J, Shen R, LaFortune TA, Wang S, Tiao N, Kim YW, Liu JL, Ramnarian D, Yuan Y, Garcia-Echevrria C, Maira SM, Yung WK.
    Clin Cancer Res; 2012 Jan 01; 18(1):184-95. PubMed ID: 22065080
    [Abstract] [Full Text] [Related]

  • 3. Inhibitor of pan class-I PI3K induces differentially apoptotic pathways in acute leukemia cells: Shedding new light on NVP-BKM120 mechanism of action.
    Bashash D, Safaroghli-Azar A, Delshad M, Bayati S, Nooshinfar E, Ghaffari SH.
    Int J Biochem Cell Biol; 2016 Oct 01; 79():308-317. PubMed ID: 27599915
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of pan-class I phosphatidyl-inositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma.
    Zang C, Eucker J, Liu H, Coordes A, Lenarz M, Possinger K, Scholz CW.
    Leuk Lymphoma; 2014 Feb 01; 55(2):425-34. PubMed ID: 23721513
    [Abstract] [Full Text] [Related]

  • 5. Synergistic Antitumor Effect of BKM120 with Prima-1Met Via Inhibiting PI3K/AKT/mTOR and CPSF4/hTERT Signaling and Reactivating Mutant P53.
    Li Z, Xu X, Li Y, Zou K, Zhang Z, Xu X, Liao Y, Zhao X, Jiang W, Yu W, Guo W, Chen Y, Li Y, Chen M, Deng WG, Li L, Zou L.
    Cell Physiol Biochem; 2018 Feb 01; 45(5):1772-1786. PubMed ID: 29495002
    [Abstract] [Full Text] [Related]

  • 6. Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma.
    Kirstein MM, Boukouris AE, Pothiraju D, Buitrago-Molina LE, Marhenke S, Schütt J, Orlik J, Kühnel F, Hegermann J, Manns MP, Vogel A.
    Liver Int; 2013 May 01; 33(5):780-93. PubMed ID: 23489999
    [Abstract] [Full Text] [Related]

  • 7. Apoptosis resistance, mitotic catastrophe, and loss of ploidy control in Burkitt lymphoma.
    Chumduri C, Gillissen B, Richter A, Richter A, Milojkovic A, Overkamp T, Müller A, Pott C, Daniel PT.
    J Mol Med (Berl); 2015 May 01; 93(5):559-72. PubMed ID: 25548804
    [Abstract] [Full Text] [Related]

  • 8. Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines.
    Mueller A, Bachmann E, Linnig M, Khillimberger K, Schimanski CC, Galle PR, Moehler M.
    Cancer Chemother Pharmacol; 2012 Jun 01; 69(6):1601-15. PubMed ID: 22543857
    [Abstract] [Full Text] [Related]

  • 9. The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt/FoxO3a/Bim axis in chronic lymphocytic leukemia cells.
    Rosich L, Saborit-Villarroya I, López-Guerra M, Xargay-Torrent S, Montraveta A, Aymerich M, Villamor N, Campo E, Pérez-Galán P, Roué G, Colomer D.
    Haematologica; 2013 Nov 01; 98(11):1739-47. PubMed ID: 23850807
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Molecular effects of the phosphatidylinositol-3-kinase inhibitor NVP-BKM120 on T and B-cell acute lymphoblastic leukaemia.
    Pereira JK, Machado-Neto JA, Lopes MR, Morini BC, Traina F, Costa FF, Saad ST, Favaro P.
    Eur J Cancer; 2015 Sep 01; 51(14):2076-85. PubMed ID: 26238016
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Activity of BKM120 and BEZ235 against Lymphoma Cells.
    Civallero M, Cosenza M, Pozzi S, Bari A, Ferri P, Sacchi S.
    Biomed Res Int; 2015 Sep 01; 2015():870918. PubMed ID: 26557706
    [Abstract] [Full Text] [Related]

  • 17. PI3K Abrogation Using Pan-PI3K Inhibitor BKM120 Gives Rise to a Significant Anticancer Effect on AML-Derived KG-1 Cells by Inducing Apoptosis and G2/M Arrest.
    Sadeghi S, Esmaeili S, Pourbagheri-Sigaroodi A, Safaroghli-Azar A, Bashash D.
    Turk J Haematol; 2020 Aug 28; 37(3):167-176. PubMed ID: 32160736
    [Abstract] [Full Text] [Related]

  • 18. Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia.
    Lonetti A, Antunes IL, Chiarini F, Orsini E, Buontempo F, Ricci F, Tazzari PL, Pagliaro P, Melchionda F, Pession A, Bertaina A, Locatelli F, McCubrey JA, Barata JT, Martelli AM.
    Leukemia; 2014 Jun 28; 28(6):1196-206. PubMed ID: 24310736
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Inhibition of PI3K/AKT signaling using BKM120 reduced the proliferation and migration potentials of colorectal cancer cells and enhanced cisplatin-induced cytotoxicity.
    Khameneh SC, Sari S, Razi S, Yousefi AM, Bashash D.
    Mol Biol Rep; 2024 Mar 14; 51(1):420. PubMed ID: 38483663
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.